title: [Influence of rhinologic usual and unusual drugs on fibroblasts from nasal polyps in cell culture].
abstract: BACKGROUND
  Nasal polyposis is treated by surgery and/or by medication but in parts without permanent remission. Fibroblasts and their proliferation are involved in the complex mechanism of polyp genesis. Therefore we have analysed the influence of 12 medications on fibroblasts from nasal polyps growing in vitro.
  
  
  METHODS
  Nasal polyps, obtained during usual surgical procedure, are enzymatically digested and cultured in serum containing media. The growing cells are identified as fibroblasts using flow cytometry with a AS02-FITC antibody (Dianova). The analysis is achieved with 5 - 6 different fibroblast cultures in each medicament tested, mostly using concentrations of the active substance from 0.006 to 1.333 mg/ml. The fibroblasts are cultured 4 days in the presence of active substances or as controls. Finally the cells are trypsinated and counted.
  
  
  RESULTS
  Mometason, Beclomethason, Fluticason, Verapamil and Timolol are the group with the strongest reduction of fibroblasts. Mometason shows a reduction to 6 % of controls at a concentration of 30 micro g/ml whereas the reduction at this concentration amounts to 30 - 60 % in the other members of this group. Mesazalin, Methylprednisolone and Pentoxifylline demonstrate the smallest influence; Prednisolon-21-hydrogen-succinate, Pilocarpin, Piroxicam and Diclofenac show an effect on a middle level.
  
  
  CONCLUSIONS
  A strong reduction of fibroblasts from nasal polyps in vitro is possible with usual rhinological medicaments but also with unusual substances in this field.
authors.affiliation: HNO-Klinik und Poliklinik Otto Körner der Universität Rostock. juergen.ostwald@med.uni-rostock.de
authors.forename: J
authors.initials: J
authors.lastname: Ostwald
authors.forename: S
authors.initials: S
authors.lastname: Graumüller
authors.forename: S
authors.initials: S
authors.lastname: Dommerich
authors.forename: M
authors.initials: M
authors.lastname: Hoff
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000730:Androstadienes / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001507:Beclomethasone / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D002478:Cells, Cultured; D003470:Culture Media; D004008:Diclofenac / Q000494:pharmacology / Q000627:therapeutic use; D005347:Fibroblasts / Q000187:drug effects*; D000068298:Fluticasone; D005938:Glucocorticoids; D006401:Hematologic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D019804:Mesalamine / Q000494:pharmacology / Q000627:therapeutic use; D008775:Methylprednisolone / Q000494:pharmacology / Q000627:therapeutic use; D000068656:Mometasone Furoate; D018721:Muscarinic Agonists / Q000494:pharmacology / Q000627:therapeutic use; D009298:Nasal Polyps / Q000188:drug therapy*; D010431:Pentoxifylline / Q000494:pharmacology / Q000627:therapeutic use; D010862:Pilocarpine / Q000494:pharmacology / Q000627:therapeutic use; D010894:Piroxicam / Q000494:pharmacology / Q000627:therapeutic use; D011239:Prednisolone / Q000494:pharmacology / Q000627:therapeutic use; D011244:Pregnadienediols / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D013999:Timolol / Q000494:pharmacology / Q000627:therapeutic use; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D002121:Calcium Channel Blockers; D003470:Culture Media; D005938:Glucocorticoids; D006401:Hematologic Agents; D018721:Muscarinic Agonists; D011244:Pregnadienediols; D010862:Pilocarpine; D000068656:Mometasone Furoate; D010894:Piroxicam; D004008:Diclofenac; D019804:Mesalamine; D013999:Timolol; D011239:Prednisolone; D014700:Verapamil; D000068298:Fluticasone; D001507:Beclomethasone; D010431:Pentoxifylline; D008775:Methylprednisolone